ProfileGDS5678 / 1449413_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 74% 73% 73% 72% 74% 77% 74% 74% 73% 72% 73% 73% 74% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.762974
GSM967853U87-EV human glioblastoma xenograft - Control 24.6965173
GSM967854U87-EV human glioblastoma xenograft - Control 34.699273
GSM967855U87-EV human glioblastoma xenograft - Control 44.7446972
GSM967856U87-EV human glioblastoma xenograft - Control 54.8864474
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0882777
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8010174
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7745774
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7529673
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6463572
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.7537373
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6996273
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7629874
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7572874